UC Davis
UC Davis Previously Published Works

Title

Regulation of voltage-gated potassium channels in vascular smooth muscle during hypertension and metabolic disorders

Permalink

https://escholarship.org/uc/item/8wd0518x

Journal

Microcirculation, 25(1)

ISSN

1073-9688

Authors

Nieves-Cintrón, Madeline
Syed, Arsalan U
Nystoriak, Matthew A
et al.

Publication Date

2018

DOI

10.1111/micc.12423

Peer reviewed

eScholarship.org Powered by the California Digital Library
University of California

HHS Public Access

Author manuscript

Microcirculation. Author manuscript; available in PMC 2019 January 01.

Published in final edited form as:

Microcirculation. 2018 January ; 25(1): . doi:10.1111/micc.12423.

Regulation of voltage-gated potassium channels in vascular smooth muscle during hypertension and metabolic disorders

Madeline Nieves-Cintrón[1,*], **Arsalan U. Syed**[1], **Matthew A. Nystoriak**[2], and **Manuel F. Navedo**[1,*]

[1]Department of Pharmacology, University of California, Davis, CA 95616

[2]Diabetes and Obesity Center, Department of Medicine, University of Louisville, Louisville, KY 40202

Abstract

Voltage-gated potassium (K_V) channels are key regulators of vascular smooth muscle contractility and vascular tone, and thus have major influence on the microcirculation. K_V channels are important determinants of vascular smooth muscle membrane potential (E_m). A number of K_V subunits are expressed in the plasma membrane of smooth muscle cells. Each subunit confers distinct kinetics and regulatory properties that allow for fine control of E_m to orchestrate vascular tone. Modifications in K_V subunit expression and/or channel activity can contribute to changes in vascular smooth muscle contractility in response to different stimuli and in diverse pathological conditions. Consistent with this, a number of studies suggest alterations in K_V subunit expression and/or function as underlying contributing mechanisms for small resistance artery dysfunction in pathologies such as hypertension and metabolic disorders, including diabetes. Here, we review our current knowledge on the effects of these pathologies on K_V channel expression and function in vascular smooth muscle cells, and the repercussions on (micro)vascular function.

Introduction

The microcirculation is greatly influenced by vascular smooth muscle cells lining the arterial wall of small resistance arteries and arterioles. The contractile state of vascular smooth muscle determines the diameter of these vessels and helps establish the level of vascular tone. This contributes to proper regulation of blood pressure and blood flow to meet metabolic demands of surrounding tissue. The association of microvascular dysfunction in humans with a number of pathological conditions, including hypertension and diabetes, underscores the significance of this mechanism (40, 47, 67).

Vascular tone is largely determined by a dynamic interplay between different ionic conductances in vascular smooth muscle that help control its membrane potential (E_m) and the level of intracellular calcium (Ca^{2+}) (75). Accordingly, the activity of potassium (K^+) channels, including a number of voltage-gated K^+ (K_V) channels, is a major regulator of vascular smooth muscle $E_{m\ (38)}$. K_V channels, through their regulation of E_m, have a major

*Correspondence to: Manuel F. Navedo, PhD, Department of Pharmacology, University of California, Davis, One Shields Avenue, Davis, CA 95616, mfnavedo@ucdavis.edu, Tel. 530-752-6880, Fax. 530-752-7710.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

influence on intracellular Ca^{2+} by modulating the open probability of L-type Ca^{2+} channels (and perhaps T-type channels (25)). This is important as Ca^{2+} influx through L-type Ca^{2+} channel $Ca_V1.2$ (e.g. Ca^{2+} sparklets) is essential for vascular smooth muscle contraction (3, 37, 52). Physiological activation of K_V channels hyperpolarizes and relaxes vascular smooth muscle by decreasing the activity of voltage-gated Ca^{2+} channels and therefore Ca^{2+} influx, whereas their inhibition promotes contraction (56). Thus, K_V channels are important regulators vascular tone.

K_V channels represent a diverse group of membrane proteins, with 12 distinct families identified to date (K_V1-K_V12) (24). Each K_V channel comprises a K_V α subunit that forms the ion conducting pore and an ancillary K_V β subunit that modulates activity of K_V α subunits. The K_V α subunit consists of six transmembrane helices (S1-S6) with the S4 transmembrane domain containing the voltage sensor. A tetramer of K_V α subunits forms the ion-conducting pore, through interactions of the S6 domain and the P-loop between the S5 and S6 domains. Vascular smooth muscle cells express a variety of K_V channels in different vascular beds, including K_V1 ($K_V1.1$, $K_V1.2$, $K_V1.3$, $K_V1.5$, $K_V1.6$), K_V2 ($K_V2.1$) as well as members of the K_V7 (K_V 7.1-5) and silent K_V subunits ($K_V9.3$) (Table 1) (2, 5, 15, 75, 81). K_V channels can exist as homo- or heterotetramers with distinct biophysical and pharmacological properties. In vascular smooth muscle, for example, $K_V1.2$ and $K_V1.5$, as well as $K_V7.4$ and $K_V7.5$ can form heteromeric channels with profound implications for cell excitability (36, 75). Likewise, co-assembly with auxiliary K_V β subunits and silent K_V subunits confers further functional diversity (36).

K_V channels represent key substrates underlying vascular smooth muscle excitability in response to not only pressure-induced depolarization (e.g. vascular tone), but also vasoactive substances. For example, K_V channels have been shown to participate in the response to vasodilators such as adenosine and β-adrenergic agonists. These vasodilators promote cAMP production, activation of protein kinase A (PKA) and phosphorylation of K_V channels to positively modulate K_V function to promote vasodilation (1). K_V inhibitors also blunt nitric oxide (NO)-induced arterial dilation, suggesting that K_V channels, at least partially mediate NO-dependent vasorelaxant effects in some vascular beds (21, 68, 70). Conversely, molecules that activate protein kinase C (PKC) are generally associated with K_V channel inhibition and membrane potential depolarization. For example, the potent vasoactive peptide angiotensin II and elevations in extracellular glucose have been shown to induce vasoconstriction, at least in part by inhibiting K_V channels through a PKC-mediated pathway (16, 65, 71). Therefore, changes in the expression of one or more K_V subunits or signaling pathways regulating K_V function may impact vascular smooth muscle excitability and (micro)vascular function during physiological and pathological conditions. K_V channel remodeling could represent an underlying mechanism for microvascular dysfunction affecting vascular tone and blood flow leading to organ damage. In support of this, studies using animal models have shown that modifications in K_V channel expression and/or function can contribute to changes in vascular smooth muscle contractility during different pathological conditions such as hypertension and metabolic disorders, including diabetes. Here, we review our current knowledge related to the changes in K_V expression and function in vascular smooth muscle cells associated with hypertension and metabolic disorders, and its repercussions on (micro)vascular function. The role of K_V channels in pulmonary artery

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

hypertension and in the renal vasculature will not be addressed here, but extensive, recent reviews on the subject can be found elsewhere (26, 46, 50, 66).

Vascular voltage-gated K_V channels in hypertension

In hypertension, the function of the microcirculation is altered. Enhanced vascular tone and reduced vasodilator response have been suggested to contribute, at least in part, to impaired tissue perfusion and end-organ damage during this pathological condition (40). Changes in K_V channel expression and/or function may contribute to this outcome. A reduction in K_V channel activity during hypertension has been reported in vascular smooth muscle from rat mesenteric arteries (9, 19, 32, 79), rat thoracic aorta (17, 32) mouse aortic arteries (48), rat renal arteries (12, 45), rat pial arteries (4, 74), mouse mesenteric arteries (32, 48) and mouse pial arteries (4). These changes are independent of the animal model employed. An early study however, reported augmentation of K_V channel activity in hypertensive vascular smooth muscle (18). The difference between this study and the rest has been attributed to methodological differences associated with intracellular Ca^{2+} levels that mediate K_V channel inhibition. This was not apparent in subsequent work examining the influence of intracellular Ca^{2+} on K_V channel function in hypertensive vascular smooth muscle from the same arterial bed (9). Thus, additional research is still required to further elucidate this conundrum.

The mechanisms for changes in K_V channel activity in hypertensive vascular smooth muscle have been associated, at least in part, with altered expression in the mRNA and/or protein levels of one or more of the K_V subunits underlying the K_V current in these cells. A reduction in the expression of mRNA and/or protein levels for $K_V1.2$, $K_V1.5$ or both subunits has been found in different vascular beds from genetic animal models of hypertension (8, 74, 79). A number of other studies have reported downregulation of $K_V2.1$ subunit mRNA/protein expression with no apparent change in $K_V1.X$ levels in cerebral and mesenteric arteries from an angiotensin II-induced hypertension model and a genetic mouse model of hypertension, respectively (4, 5, 48). More recently, downregulation in the expression of $K_V7.4$ was suggested to contribute to increased vascular smooth muscle contractility in spontaneous hypertensive rats (12, 32, 35). These results suggest a key role for several K_V subunits in the regulation of K_V currents, vascular smooth muscle contraction, and vascular reactivity during hypertension. Furthermore, they underscore the importance of the methodological conditions, species, animal models of hypertension and vascular beds in the development of experimental design and interpretation of results.

Detailed mechanistic information for changes in $K_V2.1$ expression in vascular smooth muscle from pial and mesenteric arteries during angiotensin II-induced hypertension involving the activation of the Ca^{2+}-dependent calcineurin - **n**uclear **f**actor of **a**ctivated **T** cells isoform **c3** (NFATc3) signaling pathway (Figure 1) (4, 5). Accordingly, chronic activation of angiotensin II signaling mediated by targeted PKC stimulates L-type Ca^{2+} channel activity leading to enhanced Ca^{2+} influx and calcineurin activity (51, 53). Calcineurin-mediated dephosphorylation of the transcription factor NFATc3 promotes its nuclear translocation (57). Once in the nucleus, NFATc3 suppresses the expression of $K_V2.1$ mRNA and protein levels, which results in decreased voltage-dependent K^+ currents.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Decreased $K_V2.1$ function leads to membrane depolarization, further activation of L-type Ca^{2+} channels and Ca^{2+} influx (4, 57). This may create a positive feedback loop that could potentially perpetuate the pathological signal. This loop may be interrupted by inhibition of L-type Ca^{2+} channels, calcineurin or NFATc3 (4). Conversely, the molecular mechanisms underlying alterations in K_V1.X and K_V7.X subunit expression in vascular smooth muscle during hypertension are unclear, and will certainly need further scrutiny. Moreover, given that most studies use rodent male tissues/cells, it will be important to extend studies to samples using female tissue, and when possible, the human vasculature.

Vascular voltage-gated K_V channels in metabolic disorders

As with hypertension, changes in the function of the microcirculation are also apparent in metabolic disorders. Diet-mediated changes in plasma membrane lipid composition may impact cellular function by influencing the activity of ion channels, including K_V channels (39, 69). Initial studies suggested a reduction in K^+ channel function in rabbit portal vein smooth muscle during dietary hypercholesterolemia (20) and in the mouse aorta from a genetic mouse model of atherosclerosis (34). Subsequently, a reduction in vascular K_V channel function was confirmed in arteries and arterioles from animal models of diet-induced hypercholesterolemia, obesity and metabolic syndrome (7, 22, 28, 29, 33, 60, 77). This reduction in vascular K_V channel function resulted in impaired coronary vasodilation and blood flow during diet-induced metabolic syndrome (7, 60), aberrant adenosine-mediated dilation of porcine coronary arteries and arterioles in animal models of hypercholesterolemia (22, 29) that is not corrected with exercise (28, 77), and reduced sildenafil and sodium nitroprusside-induced penile artery relaxation in a genetic model of metabolic syndrome (33). Interestingly, K_V channel function in coronary smooth muscle varies under basal conditions, in response to diet and vasoactive molecules, and during exercise in a sex-dependent manner (27, 77).

For the most part, the mechanisms underlying aberrant K_V channel function in smooth muscle cells during diet-induced hypercholesterolemia, obesity and metabolic syndrome are unclear. No change in the mRNA expression of K_V subunits in coronary arterioles has been observed in a Yucatan swine model of hypercholesterolemia (28). Rather, it was suggested that changes in the signaling pathway by which adenylyl cyclase regulates K_V channel activity seemed to contribute to impaired adenosine-mediated vasodilation of coronary arterioles in this animal model (28). In contrast, a reduction in protein levels of $K_V1.5$ in coronary arteries was associated with decreased K_V channel function, leading to impaired coronary blood flow in an Ossabaw swine model of metabolic syndrome (7). The differences between these two studies may be accounted for by differences in the extent of metabolic abnormalities in response to diet between animal models (55). More recently, altered function of K_V7 channels, but not changes in mRNA or protein expression levels, was suggested to contribute to impaired dilation in different arterial beds in several animal models of metabolic syndrome (33, 60). These studies raise important questions about the specific mechanisms underlying altered K_V channel activity in smooth muscle that contribute to impair vasodilation during metabolic disorders, which may be the basis for future experiments. Therefore, a concerted effort should be undertaken to rigorously assess the effects of changes in vascular smooth muscle membrane lipid composition as well as

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

cholesterol content, as a potential mechanism impacting its fluidity and ion channel function, including that of K_V channels.

Vascular voltage-gated K_V channels in hyperglycemia

High blood glucose (e.g. hyperglycemia) is a major metabolic abnormality that contributes to vascular complications in diabetes. Changes in extracellular glucose content may have a major impact on K_V channel function and vascular reactivity. Accordingly, studies have demonstrated distinctive regulation of K_V channel function in vascular smooth muscle cells from several vascular beds in response to acute and chronic elevations in extracellular glucose concentration (31, 41-43, 58, 65, 71, 72). During acute increases in extracellular glucose, K_V channel activity is inhibited in vascular smooth muscle cells from small diameter mesenteric arteries and cerebral parenchymal arterioles (31, 65, 71). This glucose-mediated inhibition of K_V channels is concentration dependent and resulted in vascular smooth muscle E_m depolarization (31, 65), leading to enhanced vasoconstriction (31, 71) (also see Figure 2) and impaired neurovascular coupling (71). The mechanism underlying the reduction in K_V channel activity in response to acute increases in extracellular glucose did not appear to depend on changes in K_V subunit expression, but was attributed to a PKC-dependent pathway (31, 65, 71). More recently, a study revealed that differential engagement of PKCβ and PKCα isoforms may contribute to inhibition of K_V channels in a glucose concentration-dependent manner (31). However, whether glucose-mediated inhibition of K_V channel function is due to direct K_V subunit phosphorylation or activation of a different PKC-dependent pathway is unclear. Furthermore, and in contrast to the proposed PKC-mediated inhibition of K_V channels in response to elevated glucose, we recently found that PKA activity was necessary for glucose-induced vasoconstriction of cerebral parenchymal arterioles (Figure 2). These results are consistent with recent work in pial arteries (62), and suggest an unexpected role for PKA in vasoconstriction of these small resistance arteries that requires further investigation.

A reduction in the function of K_V channels in response to chronic elevations in extracellular glucose has also been reported for vascular smooth muscle from small coronary and cerebral arteries (41-43, 58, 72). Interestingly, multiple pathways have been described to account for reduced K_V channel activity in response to chronic hyperglycemia. Earlier studies correlated a reduction in K_V currents in vascular smooth muscle of small coronary arteries incubated in elevated glucose for 24 hours to glucose-mediated production of superoxide and peroxynitrite. This was associated with specific nitration of the $K_V1.2$ subunit (with no change in $K_V1.2$ or $K_V1.5$ protein expression), impairment of K_V channel function and loss of cAMP-mediated dilation of small coronary arteries (41-43). A recent study using primary coronary vascular smooth muscle cells incubated in elevated glucose for 48 hours, linked the reduction in K_V channel function to a decrease in $K_V1.2$ and $K_V1.5$ mRNA and protein levels (72). This process was mediated by advanced glycation end products (AGE) and required AGE interaction with its surface receptor RAGE (72). A reduction in $K_V2.1$ mRNA expression was observed in mouse cerebral arteries incubated in elevated glucose for 48 hours through a mechanism that requires targeting of the phosphatase calcineurin by the scaffold protein A kinase anchoring protein 150 (AKAP150) (Figure 3) (58). On the other hand, the effects of acute and chronic elevations in extracellular glucose on K_V7 function are

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

poorly understood and require additional studies. Nevertheless, the differences in mechanisms between the aforementioned studies (even in cells/arteries from the same vascular bed) may be due to experimental conditions and use of distinct animal models. Furthermore, these observations also raise the possibility that different mechanisms may synergize to impair K_V channel function and vascular reactivity during chronic elevations in extracellular glucose with major implications for vascular complications in diabetes.

Vascular voltage-gated K_V channels in diabetes

The function of vascular smooth muscle cells in the microcirculation during diabetes is impaired (47), and changes in K_V channel expression and/or function may contribute to this outcome. Indeed, the bulk of the published data suggest a reduction in K_V channel function in smooth muscle from different vascular beds and in several models of diabetes (10, 11, 13, 58, 72). Not surprisingly and similar to chronic hyperglycemia, multiple mechanisms have been described to account for altered K_V channel activity in vascular smooth muscle during diabetes. In a rat model of type 1 diabetes (e.g. streptozotocin-induced diabetes), a reduction in K_V channel function in vascular smooth muscle from small coronary arteries was associated with downregulation of $K_V1.2$ subunit expression and increased $K_V1.2$ nitration (but not $K_V1.5$) due to enhanced superoxide production (10, 11). This was shown to contribute to impaired cAMP-mediated dilation (10, 11, 13). Interestingly, treatment with the anti-oxidant compound Ebselen decreased $K_V1.2$ nitration, and improved $K_V1.2$ expression, K_V channel activity as well as cAMP-mediated coronary dilation, in type 1 diabetic rats (11). These results suggest a potential beneficial effect of Ebselen in treating vascular complications during diabetes.

In a high fat diet (HFD) rat model of type 2 diabetes however, aberrant K_V channel activity in coronary vascular smooth muscle and impaired small coronary artery dilation were correlated with reduced mRNA and protein levels of $K_V1.2$ and $K_V1.5$ subunits (72). In this study, altered K_V subunit expression, K_V channel function and forskolin-mediated coronary artery dilation during diabetes were ameliorated in diabetic rats treated with the AGE inhibitor aminoguanidine (72). Interestingly, aminoguanidine treatment did not improve blood pressure in diabetic rats when compared to non-diabetic rats, perhaps suggesting a distinct role for AGEs in regulation of K_V channels or any other target in different vascular beds. No changes in K_V subunit expression, K_V channel function and forskolin-mediated coronary artery dilation were observed in arteries/cells from non-diabetic rats treated with aminoguanidine. These results suggest that excessive production of AGEs may be an upstream pathological signal leading to impaired K_V channel function and coronary artery reactivity during diabetes.

Alterations in K_V channel function and impaired vascular reactivity were also described for cerebral and mesenteric arteries in a HFD mouse model of type 2 diabetes (58). In this study, selective transcriptional suppression and reduced protein levels of the $K_V2.1$ subunit (but not $K_V1.2$ and $K_V1.5$) were associated with impaired K_V currents and enhanced vascular tone during diabetes. This result is important as changes in $K_V2.1$ expression and function may have prominent effects on intracellular Ca^{2+} and E_m regulation, as revealed by mathematical simulation experiments (49, 61). The mechanisms underlying this selective suppression of

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

K_V2.1 expression and function are dependent on L-type Ca^{2+} channel activity and targeting of PKA and calcineurin by AKAP150 (Figure 3) (54, 58, 62). Accordingly, a PKA-mediated increase in Ca^{2+} influx through L-type Ca^{2+} channels activates a subpopulation of AKAP150-targeted calcineurin (54, 62). Calcineurin then dephosphorylates NFATc3 and promotes its nuclear translocation (61). Once in the nucleus, NFATc3 can downregulates K_V2.1 mRNA expression, leading to a reduction in K_V2.1 protein levels and impaired K_V channel function (58). As is the case in hypertension, blocking L-type Ca^{2+} channels, preventing the interaction between calcineurin and AKAP150 or inhibiting NFATc3 could disrupt this pervasive pathway. Taken together, all of these studies on K_V function leading to vascular complications during diabetes reveal fundamental differences and divergent mechanisms that vary between vessels and animal models. Thus, the relative contributions of all of the aforementioned pathways to altered K_V channel expression and function during diabetes should be carefully evaluated and integrated.

Conclusions

K_V channels represent major substrates underlying vascular smooth muscle excitability in small resistance arteries and arterioles. Under physiological conditions, the ability of K_V channels to respond to pressure-induced depolarization, as well as to vasoactive molecules, such as vasodilators and/or vasoconstrictors, helps maintain a delicate balance between constriction and relaxation of small resistance arteries and arterioles that is necessary for appropriate myogenic response and tissue perfusion. Not surprisingly, alterations in K_V channel function have been associated with impaired vascular reactivity in a variety of diseases affecting the vasculature. K_V channel function is impaired in hypertension and in several metabolic disorders, including diabetes. The mechanisms underlying impaired K_V channel function in different pathological conditions (i.e. hypertension vs. diabetes) are variable. This most likely reflects the activation of unique signaling pathways that distinctively impact K_V expression and/or function in vascular smooth muscle cells for a specific disease. Interestingly, different mechanisms have also been reported to account for changes in K_V expression and/or function within the same pathological condition. The differences, in this case, may be related to different experimental conditions, use of cells from different vascular beds, and /or the disease state at which the experiments were performed. Regardless of the cause, these observations indicate that a single mechanism does not account for all the remodeling in K_V function during a pathological condition and suggest that multiple pathways could synergize to alter K_V channel activity with major implications for vascular smooth muscle membrane potential and vascular reactivity, particularly in the microcirculation. Therefore, further research is required to completely appreciate mechanisms underlying alteration in K_V channel activity in disease states.

Given the diverse population of homo- and heteromeric K_V channels in vascular smooth muscle from small resistance arteries, additional approaches are necessary to tease out and integrate the specific contribution of each subunit to the regulation of membrane potential and vascular tone in health and disease. Computational approaches, as well as variations of the membrane-clamp sequential dissection technique, which have been extensively employed in the cardiac field (6, 23, 49), can be implemented to quantify the relative contribution of each K_V subunit that may interact non-linearly to regulate vascular smooth

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

muscle excitability and vascular reactivity. In addition, the development of optical sensors that can selectively report the activity of different K_V subunits in response to changes in membrane potential in live cells may aid in this task (73). Future studies should also address in more detail differences in K_V function between sexes and vascular beds. Improved understanding on how inflammation and oxidative stress, which are processes common to many disease states, impact K_V channel activity in native cells is also needed. The modulation of K_V channels in vascular smooth muscle by differences in lipid membrane composition and its regulatory mechanisms, which may ensue in certain pathological conditions, has to be further explored. A recent study in HEK cells revealed a complex, yet functionally relevant interaction between phosphatidylinositol 4,5-bisphosphate (PIP_2) and the G protein βγ subunit in control of K_V7.4 channel activity (64). Whether this interaction between PIP_2, Gβγ and K_V7 or any other K_V channel also occurs in native vascular smooth muscle to play a role during pathological conditions is not clear and should be addressed in future research. Finally, the expression, function, and regulation of K_V channels in human vascular smooth muscle from small resistance arteries and arterioles should be comprehensively examined. This may reveal novel mechanisms regulating K_V channel function in health and disease. A recent study using vascular smooth muscle from coronary arterioles of patients with coronary artery disease suggested a key role for K_V1.5 in vascular reactivity and revealed that altered K_V channel function in these cells was not due to changes in K_V1.5 expression, but to reduced surface localization of this subunit (59). Thus, a better understanding of the mechanisms underlying alterations in K_V function in human small resistance arteries and arterioles may lead to the identification of potential novel therapeutic targets to “correct” K_V dysfunction and treat (micro)vascular complications during pathological conditions.

Acknowledgments

We thank Miss Maria Paz Prada for reading the manuscript. This work was supported by NIH grants R01-HL098200 and R01-HL121059 and AHA grant 14GRNT18730054 (to MFN), NIH grant T32HL086350 (to AUS and MAN), AHA 16SDG27260070 (to MAN) and a UC Davis Academic Federation Innovative Development Award (to MN-C).

References

1. Aiello EA, Walsh MP, Cole WC. Phosphorylation by protein kinase A enhances delayed rectifier K+ current in rabbit vascular smooth muscle cells. Am J Physiol. 1995; 268:H926–934. [PubMed: 7864221]
2. Albarwani S, Nemetz LT, Madden JA, Tobin AA, England SK, Pratt PF, Rusch NJ. Voltage-gated K^+ Channels in Rat Small Cerebral Arteries: Molecular Identity of the Functional Channels. J Physiol. 2003
3. Amberg GC, Navedo MF, Nieves-Cintrón M, Molkentin JD, Santana LF. Calcium Sparklets Regulate Local and Global Calcium in Murine Arterial Smooth Muscle. J Physiol. 2007; 579:187–201. [PubMed: 17158168]
4. Amberg GC, Rossow CF, Navedo MF, Santana LF. NFATc3 Regulates Kv2.1 Expression in Arterial Smooth Muscle. J Biol Chem. 2004; 279:47326–47334. [PubMed: 15322114]
5. Amberg GC, Santana LF. Kv2 channels oppose myogenic constriction of rat cerebral arteries. Am J Physiol Cell Physiol. 2006; 291:C348–356. [PubMed: 16571867]
6. Banyasz T, Horvath B, Jian Z, Izu LT, Chen-Izu Y. Sequential dissection of multiple ionic currents in single cardiac myocytes under action potential-clamp. J Mol Cell Cardiol. 2011; 50:578–581. [PubMed: 21215755]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

7. Berwick ZC, Dick GM, Moberly SP, Kohr MC, Sturek M, Tune JD. Contribution of voltage-dependent K(+) channels to metabolic control of coronary blood flow. J Mol Cell Cardiol. 2012; 52:912–919. [PubMed: 21771599]
8. Bratz IN, Dick GM, Partridge LD, Kanagy NL. Reduced molecular expression of K(+) channel proteins in vascular smooth muscle from rats made hypertensive with N{omega}-nitro-L-arginine. Am J Physiol Heart Circ Physiol. 2005; 289:H1277–1283. [PubMed: 15792990]
9. Bratz IN, Swafford AN Jr, Kanagy NL, Dick GM. Reduced functional expression of K(+) channels in vascular smooth muscle cells from rats made hypertensive with N{omega}-nitro-L-arginine. Am J Physiol Heart Circ Physiol. 2005; 289:H1284–1290. [PubMed: 15879481]
10. Bubolz AH, Li H, Wu Q, Liu Y. Enhanced oxidative stress impairs cAMP-mediated dilation by reducing Kv channel function in small coronary arteries of diabetic rats. Am J Physiol Heart Circ Physiol. 2005; 289:H1873–1880. [PubMed: 15937095]
11. Bubolz AH, Wu Q, Larsen BT, Gutterman DD, Liu Y. Ebselen reduces nitration and restores voltage-gated potassium channel function in small coronary arteries of diabetic rats. Am J Physiol Heart Circ Physiol. 2007; 293:H2231–2237. [PubMed: 17675568]
12. Chadha PS, Zunke F, Zhu HL, Davis AJ, Jepps TA, Olesen SP, Cole WC, Moffatt JD, Greenwood IA. Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired beta-adrenoceptor-mediated relaxation of renal arteries in hypertension. Hypertension. 2012; 59:877–884. [PubMed: 22353613]
13. Chai Q, Liu Z, Chen L. Effects of streptozotocin-induced diabetes on Kv channels in rat small coronary smooth muscle cells. The Chinese journal of physiology. 2005; 48:57–63. [PubMed: 15973968]
14. Cheong A, Dedman AM, Beech DJ. Expression and function of native potassium channel [K(V)alpha1] subunits in terminal arterioles of rabbit. J Physiol. 2001; 534:691–700. [PubMed: 11483700]
15. Cheong A, Dedman AM, Xu SZ, Beech DJ. K(V)alpha1 channels in murine arterioles: differential cellular expression and regulation of diameter. Am J Physiol Heart Circ Physiol. 2001; 281:H1057–1065. [PubMed: 11514271]
16. Clement-Chomienne O, Walsh MP, Cole WC. Angiotensin II activation of protein kinase C decreases delayed rectifier K+ current in rabbit vascular myocytes. J Physiol. 1996; 495(Pt 3):689–700. [PubMed: 8887776]
17. Cox RH. Comparison of K^+ channel properties in freshly isolated myocytes from thoracic aorta of WKY and SHR. Am J Hypertens. 1996; 9:884–894. [PubMed: 8879345]
18. Cox RH, Folander K, Swanson R. Differential expression of voltage-gated K^+ channel genes in arteries from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 2001; 37:1315–1322. [PubMed: 11358947]
19. Cox RH, Lozinskaya I, Dietz NJ. Differences in K^+ current components in mesenteric artery myocytes from WKY and SHR. Am J Hypertens. 2001; 14:897–907. [PubMed: 11587156]
20. Cox RH, Tulenko TN. Altered contractile and ion channel function in rabbit portal vein with dietary atherosclerosis. Am J Physiol. 1995; 268:H2522–2530. [PubMed: 7541962]
21. Favaloro JL, Kemp-Harper BK. Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms. Am J Physiol Heart Circ Physiol. 2009; 296:H1274–1280. [PubMed: 19252101]
22. Franke R, Yang Y, Rubin LJ, Magliola L, Jones AW. High-fat diet alters K+-currents in porcine coronary arteries and adenosine sensitivity during metabolic inhibition. Journal of cardiovascular pharmacology. 2004; 43:495–503. [PubMed: 15085060]
23. Grandi E, Sanguinetti MC, Bartos DC, Bers DM, Chen-Izu Y, Chiamvimonvat N, Colecraft HM, Delisle BP, Heijman J, Navedo MF, Noskov S, Proenza C, Vandenberg JI, Yarov-Yarovoy V. Potassium channels in the heart: structure, function and regulation. J Physiol. 2017; 595:2209–2228. [PubMed: 27861921]
24. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stuhmer W, Wang X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacological reviews. 2005; 57:473–508. [PubMed: 16382104]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

25. Harraz OF, Welsh DG. T-type Ca(2)(+) channels in cerebral arteries: approaches, hypotheses, and speculation. Microcirculation. 2013; 20:299–306. [PubMed: 23331671]
26. Hayabuchi Y. The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension. Pediatric cardiology. 2017; 38:1–14. [PubMed: 27826710]
27. Heaps CL, Bowles DK. Gender-specific K(+)-channel contribution to adenosine-induced relaxation in coronary arterioles. Journal of applied physiology. 2002; 92:550–558. [PubMed: 11796663]
28. Heaps CL, Jeffery EC, Laine GA, Price EM, Bowles DK. Effects of exercise training and hypercholesterolemia on adenosine activation of voltage-dependent K+ channels in coronary arterioles. Journal of applied physiology. 2008; 105:1761–1771. [PubMed: 18832757]
29. Heaps CL, Tharp DL, Bowles DK. Hypercholesterolemia abolishes voltage-dependent K+ channel contribution to adenosine-mediated relaxation in porcine coronary arterioles. Am J Physiol Heart Circ Physiol. 2005; 288:H568–576. [PubMed: 15458946]
30. Hu Z, Ma A, Zhang Y, Xi Y, Fan L, Wang T, Zhang T. Voltage-gated potassium+ channel expression in coronary artery smooth muscle cells of SHR and WKY. Cell Biochem Biophys. 2014; 70:1725–1731. [PubMed: 25030407]
31. Jackson R, Brennan S, Fielding P, Sims MW, Challiss RA, Adlam D, Squire IB, Rainbow RD. Distinct and complementary roles for alpha and beta isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucose. Br J Pharmacol. 2016; 173:870–887. [PubMed: 26660275]
32. Jepps TA, Chadha PS, Davis AJ, Harhun MI, Cockerill GW, Olesen SP, Hansen RS, Greenwood IA. Downregulation of Kv7.4 channel activity in primary and secondary hypertension. Circulation. 2011; 124:602–611. [PubMed: 21747056]
33. Jepps TA, Olesen SP, Greenwood IA, Dalsgaard T. Molecular and functional characterization of Kv 7 channels in penile arteries and corpus cavernosum of healthy and metabolic syndrome rats. Br J Pharmacol. 2016; 173:1478–1490. [PubMed: 26802314]
34. Jiang J, Thoren P, Caligiuri G, Hansson GK, Pernow J. Enhanced phenylephrine-induced rhythmic activity in the atherosclerotic mouse aorta via an increase in opening of KCa channels: relation to Kv channels and nitric oxide. Br J Pharmacol. 1999; 128:637–646. [PubMed: 10516643]
35. Khanamiri S, Soltysinska E, Jepps TA, Bentzen BH, Chadha PS, Schmitt N, Greenwood IA, Olesen SP. Contribution of Kv7 channels to basal coronary flow and active response to ischemia. Hypertension. 2013; 62:1090–1097. [PubMed: 24082059]
36. Kilfoil PJ, Tipparaju SM, Barski OA, Bhatnagar A. Regulation of ion channels by pyridine nucleotides. Circ Res. 2013; 112:721–741. [PubMed: 23410881]
37. Knot HJ, Nelson MT. Regulation of arterial diameter and wall [Ca^{2+}] in cerebral arteries of rat by membrane potential and intravascular pressure. J Physiol. 1998; 508:199–209. [PubMed: 9490839]
38. Knot HJ, Nelson MT. Regulation of membrane potential and diameter by voltage-dependent K^+ channels in rabbit myogenic cerebral arteries. Am J Physiol. 1995; 269:H348–355. [PubMed: 7631867]
39. Levitan I, Fang Y, Rosenhouse-Dantsker A, Romanenko V. Cholesterol and ion channels. Sub-cellular biochemistry. 2010; 51:509–549. [PubMed: 20213557]
40. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation. 2001; 104:735–740. [PubMed: 11489784]
41. Li H, Chai Q, Gutterman DD, Liu Y. Elevated glucose impairs cAMP-mediated dilation by reducing Kv channel activity in rat small coronary smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003; 285:H1213–1219. [PubMed: 12763748]
42. Li H, Gutterman DD, Rusch NJ, Bubolz A, Liu Y. Nitration and functional loss of voltage-gated K + channels in rat coronary microvessels exposed to high glucose. Diabetes. 2004; 53:2436–2442. [PubMed: 15331556]
43. Liu Y, Terata K, Rusch NJ, Gutterman DD. High glucose impairs voltage-gated K^+ channel current in rat small coronary arteries. Circ Res. 2001; 89:146–152. [PubMed: 11463721]
44. Lu Y, Hanna ST, Tang G, Wang R. Contributions of Kv1.2, Kv1.5 and Kv2.1 subunits to the native delayed rectifier K^+ current in rat mesenteric artery smooth muscle cells. Life sciences. 2002; 71:1465–1473. [PubMed: 12127166]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

45. Martens JR, Gelband CH. Alterations in rat interlobar artery membrane potential and K+ channels in genetic and nongenetic hypertension. Circ Res. 1996; 79:295–301. [PubMed: 8756007]
46. Montani D, Chaumais MC, Guignabert C, Gunther S, Girerd B, Jais X, Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M. Targeted therapies in pulmonary arterial hypertension. Pharmacology & therapeutics. 2014; 141:172–191. [PubMed: 24134901]
47. Montero D, Walther G, Perez-Martin A, Vicente-Salar N, Roche E, Vinet A. Vascular smooth muscle function in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetologia. 2013; 56:2122–2133. [PubMed: 23864267]
48. Moreno-Dominguez A, Cidad P, Miguel-Velado E, Lopez-Lopez JR, Perez-Garcia MT. De novo expression of Kv6.3 contributes to changes in vascular smooth muscle cell excitability in a hypertensive mice strain. J Physiol. 2009; 587:625–640. [PubMed: 19074965]
49. Morotti S, Nieves-Cintrón M, Nystoriak MA, Navedo MF, Grandi E. Predominant contribution of L-type Cav1.2 channel stimulation to impaired intracellular calcium and cerebral artery vasoconstriction in diabetic hyperglycemia. Channels. 2017:1–7.
50. Moudgil R, Michelakis ED, Archer SL. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation. 2006; 13:615–632. [PubMed: 17085423]
51. Navedo MF, Amberg GC. Local regulation of L-type ca(2+) channel sparklets in arterial smooth muscle. Microcirculation. 2013; 20:290–298. [PubMed: 23116449]
52. Navedo MF, Amberg GC, Westenbroek RE, Sinnegger-Brauns MJ, Catterall WA, Striessnig J, Santana LF. Cav1.3 channels produce persistent calcium sparklets, but Cav1.2 channels are responsible for sparklets in mouse arterial smooth muscle. Am J Physiol Heart Circ Physiol. 2007; 293:H1359–1370. [PubMed: 17526649]
53. Navedo MF, Nieves-Cintron M, Amberg GC, Yuan C, Votaw VS, Lederer WJ, McKnight GS, Santana LF. AKAP150 is required for stuttering persistent Ca2+ sparklets and angiotensin II-induced hypertension. Circ Res. 2008; 102:e1–e11. [PubMed: 18174462]
54. Navedo MF, Takeda Y, Nieves-Cintron M, Molkentin JD, Santana LF. Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle cells. American journal of physiology Cell physiology. 2010; 298:C211–220. [PubMed: 19846755]
55. Neeb ZP, Edwards JM, Alloosh M, Long X, Mokelke EA, Sturek M. Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine. Comparative medicine. 2010; 60:300–315. [PubMed: 20819380]
56. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995; 268:C799–822. [PubMed: 7733230]
57. Nieves-Cintron M, Amberg GC, Navedo MF, Molkentin JD, Santana LF. The control of Ca2+ influx and NFATc3 signaling in arterial smooth muscle during hypertension. Proc Natl Acad Sci U S A. 2008; 105:15623–15628. [PubMed: 18832165]
58. Nieves-Cintron M, Nystoriak MA, Prada MP, Johnson K, Fayer W, Dell'Acqua ML, Scott JD, Navedo MF. Selective downregulation of Kv2.1 function contributes to enhanced arterial tone during diabetes. Journal of Biological Chemistry. 2015; 290:7918–7929. [PubMed: 25670860]
59. Nishijima Y, Cao S, Chabowski DS, Korishettar A, Ge A, Zheng X, Sparapani R, Gutterman DD, Zhang DX. Contribution of KV1.5 Channel to Hydrogen Peroxide-Induced Human Arteriolar Dilation and Its Modulation by Coronary Artery Disease. Circ Res. 2017; 120:658–669. [PubMed: 27872049]
60. Noblet JN, Owen MK, Goodwill AG, Sassoon DJ, Tune JD. Lean and Obese Coronary Perivascular Adipose Tissue Impairs Vasodilation via Differential Inhibition of Vascular Smooth Muscle K+ Channels. Arteriosclerosis, thrombosis, and vascular biology. 2015; 35:1393–1400.
61. Nystoriak MA, Nieves-Cintron M, Nygren PJ, Hinke SA, Nichols CB, Chen CY, Puglisi JL, Izu LT, Bers DM, Dell'acqua ML, Scott JD, Santana LF, Navedo MF. AKAP150 Contributes to Enhanced Vascular Tone by Facilitating Large-Conductance Ca2+-Activated K+ Channel Remodeling in Hyperglycemia and Diabetes Mellitus. Circ Res. 2014; 114:607–615. [PubMed: 24323672]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

62. Nystoriak MA, Nieves-Cintron M, Patriarchi T, Buonarati OR, Prada MP, Morotti S, Grandi E, Dos Santos Fernandes J, Forbush K, Hofmann F, Sasse KC, Scott JD, Ward SM, Hell JW, Navedo MF. Ser1928 phosphorylation by PKA stimulates L-type Ca2+ channel Cav1.2 and vasoconstriction during acute hyperglycemia and diabetes. Science signaling. 2017; 10
63. Nystoriak MA, Zhang D, Jagatheesan G, Bhatnagar A. Heteromeric complexes of aldo-keto reductase auxiliary KVbeta subunits (AKR6A) regulate sarcolemmal localization of KV1.5 in coronary arterial myocytes. Chemico-biological interactions. 2017
64. Povstyan OV, Barrese V, Stott JB, Greenwood IA. Synergistic interplay of Gbetagamma and phosphatidylinositol 4,5-bisphosphate dictates Kv7.4 channel activity. Pflugers Arch. 2017; 469:213–223. [PubMed: 27981364]
65. Rainbow RD, Hardy ME, Standen NB, Davies NW. Glucose reduces endothelin inhibition of voltage-gated potassium channels in rat arterial smooth muscle cells. J Physiol. 2006; 575:833–844. [PubMed: 16825302]
66. Salomonsson M, Brasen JC, Sorensen CM. Role of renal vascular potassium channels in physiology and pathophysiology. Acta physiologica. 2017
67. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, Gans RO. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation. 1999; 99:896–902. [PubMed: 10027812]
68. Sobey CG, Faraci FM. Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide. Br J Pharmacol. 1999; 126:1437–1443. [PubMed: 10217538]
69. Spector AA, Yorek MA. Membrane lipid composition and cellular function. Journal of lipid research. 1985; 26:1015–1035. [PubMed: 3906008]
70. Stott JB, Barrese V, Jepps TA, Leighton EV, Greenwood IA. Contribution of Kv7 channels to natriuretic peptide mediated vasodilation in normal and hypertensive rats. Hypertension. 2015; 65:676–682. [PubMed: 25547342]
71. Straub SV, Girouard H, Doetsch PE, Hannah RM, Wilkerson MK, Nelson MT. Regulation of intracerebral arteriolar tone by K(v) channels: effects of glucose and PKC. Am J Physiol Cell Physiol. 2009; 297:C788–796. [PubMed: 19605735]
72. Su W, Li W, Chen H, Liu H, Huang H, Li H. Advanced Glycation End Products Impair Voltage-Gated K+ Channels-Mediated Coronary Vasodilation in Diabetic Rats. PLoS One. 2015; 10:e0142865. [PubMed: 26562843]
73. Tilley DC, Eum KS, Fletcher-Taylor S, Austin DC, Dupre C, Patron LA, Garcia RL, Lam K, Yarov-Yarovoy V, Cohen BE, Sack JT. Chemoselective tarantula toxins report voltage activation of wild-type ion channels in live cells. Proc Natl Acad Sci U S A. 2014; 111:E4789–4796. [PubMed: 25331865]
74. Tobin AA, Joseph BK, Al-Kindi HN, Albarwani S, Madden JA, Nemetz LT, Rusch NJ, Rhee SW. Loss of cerebrovascular Shaker-type K(+) channels: a shared vasodilator defect of genetic and renal hypertensive rats. Am J Physiol Heart Circ Physiol. 2009; 297:H293–303. [PubMed: 19411284]
75. Tykocki NR, Boerman EM, Jackson WF. Smooth Muscle Ion Channels and Regulation of Vascular Tone in Resistance Arteries and Arterioles. Comprehensive Physiology. 2017; 7:485–581. [PubMed: 28333380]
76. Xu C, Lu Y, Tang G, Wang R. Expression of voltage-dependent K(+) channel genes in mesenteric artery smooth muscle cells. Am J Physiol. 1999; 277:G1055–1063. [PubMed: 10564112]
77. Yang Y, Jones AW, Thomas TR, Rubin LJ. Influence of sex, high-fat diet, and exercise training on potassium currents of swine coronary smooth muscle. Am J Physiol Heart Circ Physiol. 2007; 293:H1553–1563. [PubMed: 17526655]
78. Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, Schwake M, Ohya S, Greenwood IA. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol. 2007; 151:758–770. [PubMed: 17519950]
79. Zhang Y, Gao YJ, Zuo J, Lee RM, Janssen LJ. Alteration of arterial smooth muscle potassium channel composition and BKCa current modulation in hypertension. European journal of pharmacology. 2005; 514:111–119. [PubMed: 15910797]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

80. Zhong XZ, Abd-Elrahman KS, Liao CH, El-Yazbi AF, Walsh EJ, Walsh MP, Cole WC. Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter. J Physiol. 2010; 588:4519–4537. [PubMed: 20876197]
81. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, Greenwood IA. Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol. 2010; 588:3277–3293. [PubMed: 20624791]

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript



Figure 1. Proposed mechanism for suppression of K_V channel expression and function during angiotensin II-induced hypertension

Under physiological conditions, expression and function of several K_V subunits, including $K_V1.X$, $K_V2.1$ and $K_V7.X$, oppose pressure-induced depolarization to limit LTCC activity and vascular smooth muscle contraction. During chronic angiotensin II signaling activation, as in hypertension, activation of PKC stimulates LTCC activity, thus increasing global Ca^{2+} influx and promoting contraction. This increase in Ca^{2+} influx can also stimulate the activation of the Ca^{2+}/calmodulin-dependent, AKAP150-targeted phosphatase calcineurin. This phosphatase dephosphorylates the transcription factor NFATc3, allowing its translocation to the nucleus. Once in the nucleus, NFATc3 can regulate gene expression, including suppression of the expression of $K_V2.1$ (but not $K_V1.2$ and $K_V1.5$) subunits. This reduces feedback membrane potential hyperpolarization leading to increased activity of LTCC and Ca^{2+} influx, vascular smooth muscle contraction and enhanced vascular tone during angiotensin II-induced hypertension. This feedback loop may be interrupted by LTCC blockers, inhibition of calcineurin or NFATc3, or disruption of the interaction between AKAP150 and calcineurin. Whether direct phosphorylation of LTCCs by PKC, as well as alterations in $K_V7.X$ expression in response to angiotensin II-induced hypertension occurs is unclear (indicated by ??). Illustration of the interaction between AKAP150 and LTCC does not necessarily reflect the native interaction between these proteins. The cartoon was drawn as such for simplicity.

Author Manuscript Author Manuscript Author Manuscript Author Manuscript



Figure 2. PKA is required for vasoconstriction of cerebral parenchymal arteries in response to elevated glucose

A) Representative diameter recordings and **B)** summary hg-induced constriction in the absence or presence of the PKA inhibitor rpcAMPs (10 μM). A solution containing 0 mM extracellular Ca^{2+} and the LTCC blocker nifedipine (1 μM) was used to obtain the passive diameter. $*P < 0.05$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



Figure 3. Model for suppression of K_V channel expression and function in diabetes

PKA-mediated phosphorylation of activation of serine 1928 induces potentiation of LTCCs in response to hyperglycemia and during diabetes (62). This leads to increased global Ca^{2+} influx and contraction. The increase in Ca^{2+} influx promotes activation of the AKAP150-targeted calcineurin, which dephosphorylates NFATc3 and allows its nuclear translocation where the transcription factor can suppress the expression of K_V2.1 (but not K_V1.2 and K_V1.5) subunits. This reduction in K_V2.1 expression and function decreases voltage-gated K^+ currents and the negative feedback membrane potential hyperpolarization, thus leading to membrane potential depolarization, further Ca^{2+} influx through LTCCs, vascular smooth muscle contraction and enhanced vascular tone. Whether changes in K_V7.X subunits during diabetes proceed through the calcineurin/NFATc3 signaling pathway and similar changes occur in the human vasculature require further investigation. Illustration of the interaction between AKAP150 and LTCC does not necessarily reflect the native interaction between these proteins. The cartoon was drawn as such for simplicity.

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Table 1

Expression of K_V subunits in blood vessels from different species

vascular bed	species	K_V subunits	references
cerebral arteries	mouse	1.2, 1.5, 1.6, 2.1	(15, 58)
	rabbit	1.5, 1.6	(14)
	rat	1.2, 1.5, 2.1, 7.4, 7.5, 9.3	(2, 4, 5, 80, 81)
mesenteric arteries	mouse	1.2, 1.5, 2.1, 6.3, 7.4	(48, 58, 78)
	rat	1.2, 1.5, 2.1	(18, 44, 76)
coronary arteries	mouse	1.2, 1.5, 2.1, 7.4, 7.5	(63, 78)
	rat	1.2, 1.5, 7.1, 7.4, 7.5	(30, 35)
	human	1.5	(59)